Compare Eli Lilly And Co (LLY) vs Toro Company (The) Common Stock (TTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Toro Company (The) Common Stock — how do they compare? Eli Lilly And Co trades at $1,227.79 (market cap $1.08T), while Toro Company (The) Common Stock trades at $98.27 (market cap $9.30B). The key difference: Eli Lilly And Co is far larger — about 116.1× Toro Company (The) Common Stock's market cap, and Toro Company (The) Common Stock pays the higher dividend (1.59%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 94 Days and Toro Company (The) Common Stock for 0 Days on average.
| LLY | TTC | |
|---|---|---|
Market Cap | $1.08T | $9.30B |
Volume | 2,520,401 | 420,909 |
Sector | Health | Industrials |
52-Week High | $1.28K | $101.76 |
52-Week Low | $799.57 | $67.99 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $1.12T | $10.20B |
Dividend Yield | 0.57% | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,166.51, down 1.36% on the day, amid a bullish technical outlook with strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 surpassing the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights advancements in weight-loss and diabetes drugs, reinforcing growth prospects.
LLY's outlook remains positive, supported by a dominant position in obesity treatments and a promising pipeline. Risks include competitive pressures and high valuation multiples. Analyst consensus is strongly bullish with a $1,350 price target, though investors should monitor execution and regulatory developments.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Toro Company (The) Common Stock
The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →
